Teriparatide inhalation - Nektar Therapeutics

Drug Profile

Teriparatide inhalation - Nektar Therapeutics

Alternative Names: Parathyroid hormone inhalation - Eli Lilly/Inhale Therapeutic Systems; PTH inhalation - Eli Lilly/Inhale Therapeutic Systems; Teriparatide inhalation - Eli Lilly/Inhale Therapeutic Systems

Latest Information Update: 12 Mar 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nektar Therapeutics
  • Developer ALZA Corporation; Eli Lilly; Nektar Therapeutics
  • Class
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 18 Feb 2003 Nektar Therapeutics is seeking a new partner for the development of teriparatide inhalation
  • 15 Jan 2003 Inhale Therapeutic Systems is now called Nektar Therapeutics
  • 27 Oct 2001 Suspended-I for Postmenopausal osteoporosis in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top